RxDoctor Payments Data

Elizabeth Henry, MD

Ophthalmology · Grand Rapids, MINPI 1598727935

Payments from drug & device makers

$4,746in general payments, 2019–2025

Across 187 payments — averaging $25.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$624
  • Amgen$468
  • Ocular Therapeutix, Inc.$437
  • Bausch & Lomb Americas Inc.$397
  • Glaukos Corporation$387
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$344
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$4,35692%
  • Other$3908%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,746 in reported general payments places this provider in the 80th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$174,198
Medicare patients
481
Services billed
1,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner83$147,243
RestasisCyclosporine77$91,861
LumiganBimatoprost106$48,395
XiidraLifitegrast35$32,243
TyrvayaVarenicline Tartrate12$22,150
Cyclosporine34$19,273
Timolol Maleate181$10,930
ErythromycinErythromycin Base904$10,578
Brimonidine Tartrate140$10,446
SimbrinzaBrinzolamide/Brimonidine Tart36$8,709
Latanoprost419$8,380
VyzultaLatanoprostene Bunod22$8,173
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat195$5,635
Travoprost21$3,905
TafluprostTafluprost/Pf11$3,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$316$147,24383 claims
AbbVieRestasis, Lumigan$292$140,255183 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$397$40,41657 claims
Oyster Point Pharma, Inc.Tyrvaya$94$22,15012 claims
AlconSimbrinza$624$8,70936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →